Biotech Values

[DewDiligence]

Pradaxa meta-analysis shows slightly increased CV risk:

http://www.reuters.com/article/2012/01/09/us-drugs-pradaxa-idUSTRE80825W20120109

The relative increase in risk to comparative medicines was found to range from 27 to 33 percent; however, the absolute risk increase for suffering a heart attack was only 0.27 percent, the authors of the meta-analysis said in the study published on Monday in the Archives of Internal Medicine online edition.

Doctors from the Cleveland Clinic conducted the meta-analysis based on data from seven clinical trials of Pradaxa involving more than 39,500 patients. The studies compared Pradaxa to either warfarin, enoxaparin - another widely used blood thinner sold under the band name Lovenox - or a placebo. The meta-analysis also found that the rate of death was lower for patients who received Pradaxa than those got other medicines in the clinical trials - 4.83 percent versus 5.02 percent in the control groups.

This has no commercial consequence, IMO.